Israel’s CytoReason Launches AI Drug Discovery Platform In Japanese Market
Israeli AI company Cytoreason develops computational disease models of the human immune system for discovery and clinical drug development.
September 30, 2021
Israeli Biotech Startup Combines Immunology, AI To Help Develop Better Drugs
Founded in 2016, CytoReason already has partnerships with top global pharmaceutical companies.
May 14, 2019
